Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT01767766 |
| Title | Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | TG Therapeutics, Inc. |
| Indications | |
| Therapies | |
| Age Groups: | adult |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| TG Therapeutics Trial Site | Sarasota | Florida | 34232 | United States | Details | |
| TG Therapeutics Trial Site | Hackensack | New Jersey | 07601 | United States | Details | |
| TG Therapeutics Trial Site | New York | New York | 10019 | United States | Details | |
| TG Therapeutics Trial Site | Durham | North Carolina | 27710 | United States | Details | |
| TG Therapeutics Trial Site | Cincinnati | Ohio | 45242 | United States | Details | |
| TG Therapeutics Trial Site | Nashville | Tennessee | 37203 | United States | Details | |
| TG Therapeutics Investigational Trial Site | Milwaukee | Wisconsin | 53226 | United States | Details |